Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)

This study has been completed.
Information provided by (Responsible Party):
Bristol-Myers Squibb Identifier:
First received: February 23, 2012
Last updated: July 4, 2014
Last verified: June 2014
The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of Brivanib in Chinese subjects with Advanced Hepatocellular Carcinoma (HCC).

Condition Intervention Phase
Hepatocellular Carcinoma
Drug: Brivanib
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: A Phase 1 Study to Determine the Safety and Pharmacokinetics of Brivanib in Chinese Subjects With Advanced Hepatocellular Carcinoma (HCC)

Resource links provided by NLM:

Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Maximum observed plasma concentration (Cmax) of Brivanib [ Time Frame: Days 1, 2, 8, 9 and 15 ] [ Designated as safety issue: No ]
  • Trough observed plasma concentration (Cmin) of Brivanib [ Time Frame: Days 1, 2, 8, 9 and 15 ] [ Designated as safety issue: No ]
  • Time of maximum observed plasma concentration (Tmax) of Brivanib [ Time Frame: Days 1, 2, 8, 9 and 15 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time zero to the end of the dosing interval [AUC(TAU)] of Brivanib [ Time Frame: Days 1, 2, 8, 9 and 15 ] [ Designated as safety issue: No ]
  • Average steady state concentration calculated as AUC(TAU)/24 (Css_av) of Brivanib [ Time Frame: Days 1, 2, 8, 9 and 15 ] [ Designated as safety issue: No ]
  • Degree of fluctuation calculated as ((Cmax- Cmin)/Css_av) [Degree of fluctuation] of Brivanib [ Time Frame: Days 1, 2, 8, 9 and 15 ] [ Designated as safety issue: No ]
  • Terminal half-life (T-HALF) of Brivanib [ Time Frame: Days 1, 2, 8, 9 and 15 ] [ Designated as safety issue: No ]
  • Accumulation index calculated as the ratio: AUC(TAU) at steady-state (Day 8) divided by AUC(TAU) after the first dose (Day 1) [AI] of Brivanib [ Time Frame: Days 1, 2, 8, 9 and 15 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Safety assessments based on adverse event reports and the results of vital sign measurements, electrocardiograms (ECGs), 2-D Echocardiograms, physical examinations and clinical laboratory tests [ Time Frame: Part A: Day 1-Week 1, Day 8-Week 2, Day 15-Week 3 and Day 29-Week 5, Part B: End of treatment (approximately 24 months) ] [ Designated as safety issue: Yes ]
  • Preliminary evidence of anti-tumor activity as measured by objective response rate (ORR) and disease control rate (DCR) in Chinese subjects with advanced HCC treated with Brivanib [ Time Frame: Screening, Week 7 and every 6 weeks up to End of treatment (approximately 24 months) ] [ Designated as safety issue: No ]

Enrollment: 17
Study Start Date: March 2012
Study Completion Date: November 2013
Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm: Brivanib Drug: Brivanib
Tablets, Oral, 800 mg, Once daily, Until withdrawal of consent, disease progression or until unmanageable toxicity
Other Name: BMS-582664


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

For more information regarding BMS clinical trial participation, please visit

Inclusion Criteria:

Subjects with:

  • Confirmed Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)
  • Not having received prior systemic treatment for advanced HCC
  • Normal or moderately impaired liver function (Child-Pugh Class A or B (CP total score of ≤ 7))
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

Exclusion Criteria:

Subjects with:

  • Brain metastasis or evidence of leptomeningeal disease
  • History of impaired brain function (encephalopathy) or active heart disease
  • Unmanageable fluid in the abdomen (ascites)
  • Bleeding esophageal or gastric varices within 2 months prior to inclusion
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01540461

China, Beijing
Local Institution
Beijing, Beijing, China, 100071
China, Heilongjiang
Local Institution
Ha Erbin, Heilongjiang, China, 150040
China, Jiangsu
Local Institution
Nanjing, Jiangsu, China, 210002
Sponsors and Collaborators
Bristol-Myers Squibb
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
Responsible Party: Bristol-Myers Squibb Identifier: NCT01540461     History of Changes
Other Study ID Numbers: CA182-064 
Study First Received: February 23, 2012
Last Updated: July 4, 2014
Health Authority: United States: Food and Drug Administration
China: State Administration of Traditional Chinese Medicine of the People's Republic of China
China: Ministry of Health

Keywords provided by Bristol-Myers Squibb:

Additional relevant MeSH terms:
Carcinoma, Hepatocellular
Digestive System Diseases
Digestive System Neoplasms
Liver Diseases
Liver Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial processed this record on May 05, 2016